Skip to main content
Advertisement
Advertisement

DMAA

D

Drugs Made In America Acquisition Corp. Ordinary Shares

10.84
USD
Sponsored
-0.01
-0.09%
Sep 25, 15:53 UTC -4
Closed
exchange

After-Market

10.84

0.00
-0.05%

DMAA Earnings Reports

Positive Surprise Ratio

No Data Available for DMAA

0%

Next Report

Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/
--
Implied change from Q2 26 (Revenue/ EPS)
--
/
--
Implied change from Q-- -- (Revenue/ EPS)
--
/
--

Drugs Made In America Acquisition Corp. Ordinary Shares earnings per share and revenue

On Aug 10, 2026, DMAA reported earnings of -- USD per share (EPS) for Q2 26, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference.
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
OFS Credit Company, Inc. 5.25% Series E Term Preferred Stock Due 2026
Report Date
Sep 17, 2026 For Q3 26
Estimate
$0.23
Actual
$0.21
Surprise
-10.49%
FAQ
For Q2 2026, Drugs Made In America Acquisition Corp. Ordinary Shares reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
The next earning report is scheduled for --.
Based on -- analysts, Drugs Made In America Acquisition Corp. Ordinary Shares is expected to report EPS of -- and revenue of -- for Q-- --.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement